063160.KS
CKD Bio Corp. [063160.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
063160.KS Stock Summary
Top 10 Correlated Stocks
063160.KS
In the News
063160.KS Financial details
Company Rating
-
Market Cap
130.29B
Income
-24.19B
Revenue
160.35B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
519
Optionable
No
Shortable
Yes
Earnings
26 Apr 2024
P/E
-5.59
Forward P/E
-
PEG
-1.25
P/S
0.81
P/B
0.98
P/C
-
P/FCF
-6.32
Quick Ratio
-
Current Ratio
1.56
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.41K
EPS next Y
-
EPS next Q
-
EPS this Y
44.84%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
3.17%
Revenue Q/Q
-16.56%
EPS Q/Q
27.18%
-
-
-
-
SMA20
5.57%
SMA50
9%
SMA100
2.9%
Inst Own
-
Inst Trans
-
ROA
-7%
ROE
-16%
ROC
-0.11%
Gross Margin
4%
Oper. Margin
-16%
Profit Margin
-14%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
19050.0-29250.0
52W High
-21.37%
52W Low
+20.73%
RSI
56
Rel Volume
0.12
Avg Volume
19.36K
Volume
2.41K
Perf Week
-1.5%
Perf Month
11.92%
Perf Quarter
-7.07%
Perf Half Y
-12.05%
-
-
-
-
Beta
1.206
-
-
Volatility
166.6%, 1259.78%
Prev Close
0%
Price
23000
Change
-0.65%
Company Profile
- Volume Average 19.36K
- Market Capitalization 130.29B
- Employee 519
- CEO Mr. Jang-Han Lee
- Headquarters Seoul,KR
- IPO Date 2000-01-04
-
Website
https://www.ckdbio.com 
CKD Bio Corp. manufactures and distributes drug substances based on fermentation, synthesis, and biotechnology in South Korea. It offers drug substances in the areas of antibiotic, ß-lactamase inhibitors, immunosuppressants, anticancer drugs, obesity treatment drugs, dry eye, antivirus, antituberculosis, antihyperlipidemics, and probiotics. The company also provides contract research and development, and manufacturing services for active pharmaceutical ingredients and intermediates, and probiotics. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea.
